Home
 /
Papers
 /
Cancer Biology
 /
A spatiotemporal cancer cell trajectory underlies glioblastoma heterogeneity
Preprint
Open access
V1
Top 1% · Validated by QED

A spatiotemporal cancer cell trajectory underlies glioblastoma heterogeneity

Grant de Jong, Fani Memi, Tannia Gracia +44 more
May 2025
 ·
bioRxiv
 ·
DOI 
10.1101/2025.05.13.653495
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Cancer Biology this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

By showing that glioblastoma's notorious heterogeneity reflects a single conserved trajectory from developmental to injury-response states, this work overturns the view that GBM diversity is tumour-specific chaos and makes cancer cell plasticity rationally tractable.

QED claims analysis

Summary

Glioblastoma heterogeneity arises from a spatiotemporally-patterned and molecularly conserved cellular trajectory in which malignant cells transition from developmental-like states at the infiltrating tumor edge to gliosis and hypoxia states at the necrotic core, a trajectory that manifests across tumor subtypes and genetically distinct subclones within individual tumors and is coupled to regionalized myeloid signaling environments.

See full analysis
Main Claim 1 –

Glioblastoma Malignant Cells Span Developmental-Like to Gliosis-Hypoxia States

Main Claim 2 –

Spatial Zonation from Dev-Like Edge to Hypoxic Necrotic Core

Supporting evidence

  • AC-Progenitor Programs Progress Through Gliosis Markers to Hypoxia Genes
Main Claim 3 –

Dev-Like and Gliosis-Hypoxia States Arise Within Same Subclones

Supporting evidence

  • Glioblastoma Subclones Are Finely Spatially Intermixed Across Tissue Niches
Main Claim 4 –

Conserved Dev-Like to Gliosis-Hypoxia Trajectory Across Tumors and Subclones

Supporting evidence

  • Malignant Trajectory Aligns with Regionalized Myeloid Compartments and Signaling

Abstract

Cancer cells display highly heterogeneous and plastic states in glioblastoma, an incurable brain tumour. However, how these malignant states arise and whether they follow defined cellular trajectories across tumours is poorly understood. Here, we generated a deep single cell and spatial multi-omic atlas of human glioblastoma that pairs transcriptomic, epigenomic and genomic profiling of 12 tumours across multiple regions. We identify that glioblastoma heterogeneity is driven by spatially-patterned transitions of cancer cells from developmental-like states towards those defined by a glial injury response and hypoxia. This cellular trajectory regionalises tumours into distinct tissue niches and manifests in a molecularly conserved manner across tumours as well as genetically distinct tumour subclones. Moreover, using a new deep learning framework to map cancer cell states jointly with clones in situ, we show that tumour subclones are finely spatially intermixed through glioblastoma tissue niches. Finally, we show that this cancer cell trajectory is intimately linked to myeloid heterogeneity and unfolds across regionalised myeloid signalling environments. Our findings define a stereotyped trajectory of cancer cells in glioblastoma and unify glioblastoma tumour heterogeneity into a tractable cellular and tissue framework.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?